Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02077751 · ClinicalTrials.gov registry record · Phase 1
BioRBC Survival in Adults With Prior Antibody Response to BioRBCs
A Phase 1 study of Anemia, sponsored by John A Widness.
- Completed
- Registry status
- Phase 1
- Development phase
- 3
- Enrollment target
- 1
- Study location
NCT02077751: Completed Phase 1 study of Anemia, sponsored by John A Widness.
NCT02077751 is a Phase 1 study of Anemia that has completed, run by John A Widness. The registered enrollment target is 3 participants, below the 428-participant average among 72 other Anemia trials with a reported enrollment target (99% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02077751, a Phase 1 study of Anemia, has completed, sponsored by John A Widness.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 3 participants
- Enrollment target
- 1
- Study location
Study Summary
Objective: To gather safety and efficacy BioRBC data from adult subjects who previously developed transient BioRBC antibody responses by redosing them and observing for adverse clinical or laboratory (i.e., a positive BioRBC antibody titer) outcomes to determine if RBC kinetic study results differ from the previous study. Hypothesis: BioRBC survival studies performed in adult subjects who previously developed a transient BioRBC antibody response will: 1) be associated with no adverse clinical or laboratory events; 2) experience a second transient, BioRBC antibody response; and 3) display a pattern of RBC survival that is identical to their prior dosing with BioRBCs at the same dose.
Conditions Studied
Interventions
- DRUG biotin labelled RBCs
Study Locations (1)
Iowa
- University of Iowa - Iowa City
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 3 participants |
| Start Date | 2013-05 |
| Est. Completion | 2019-12 |
| Phase | Phase 1 |
What the finished NCT02077751 record still lists
NCT02077751 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 3 participants, a relatively small participant target, below the 428-participant average among 72 other Anemia trials with a reported enrollment target (99% lower).
The record links to 1 condition, with Anemia appearing as the primary indexed condition, and to 1 intervention - of which biotin labelled RBCs is the first listed.
NCT02077751 reports a single indexed study location in Iowa.
Frequently Asked Questions
What is clinical trial NCT02077751 about?
NCT02077751 is a clinical study titled "BioRBC Survival in Adults With Prior Antibody Response to BioRBCs". Objective: To gather safety and efficacy BioRBC data from adult subjects who previously developed transient BioRBC antibody responses by redosing them and observing for adverse clinical or laboratory (i.e., a positive BioRBC antibody titer) outcomes to determine if RBC kinetic study results differ f...
What is the current status of trial NCT02077751?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 3 participants. The study started on 2013-05. Estimated completion is 2019-12.
What conditions does trial NCT02077751 study?
This clinical trial studies the following conditions: Anemia.
What interventions are being tested in trial NCT02077751?
The interventions under investigation include: biotin labelled RBCs (DRUG).
Who is sponsoring clinical trial NCT02077751?
This trial is sponsored by John A Widness, which has 3 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT02077751 being conducted?
This trial has 1 study location across Iowa. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Anemia
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT02077751's enrollment target sits among peer trials
3 73rd of 72 the lowest of 72 other Anemia trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Anemia trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Study of DISC-0974 (RALLY-MF) in Participants With Myelofibrosis or Myelodysplastic Syndrome and Anemia
RECRUITING · Phase 1
-
INCB000928 Administered as a Monotherapy or in Combination With Ruxolitinib in Participants With Anemia Due to Myeloproliferative Disorders
ACTIVE NOT RECRUITING · Phase 1
-
A Study of the Electrocardiogram Effects and Pharmacokinetics of Ferumoxytol in Healthy Men and Women
COMPLETED · Phase 1
-
A Phase 1 Study of LY2787106 in Cancer and Anemia
COMPLETED · Phase 1
-
Luspatercept for Anemia in Lower Risk MDS or Non-proliferative MDS/MPN Neoplasms
RECRUITING · Phase 2
-
Study of DISC-0974-201 in Participants With IBD and Anemia
RECRUITING · Phase 2
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia